Market Price

44.40 

0.28 0.6%

as of Jan 15 '21

52 Week Range:

16.24 44.83


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 0.42
0.14
0.18
0.55
0.75
0.93
1.44
1.77
2.89
growth rate -42.3% 28.6% 205.6% 36.4% 24.0% 54.8% 22.9% 63.3%
Earnings BIT 554.16
1,052.83
1,366.39
1,380.00
2,638.00
growth rate 90.0% 29.8% 1.0% 91.2%
ROA -36.89
-13.67
-29.48
-29.91
6.56
13.10
22.56
25.97
18.64
19.55
18.35
growth rate 0.0% 0.0% 0.0% 100.0% 99.7% 72.2% 15.1% -28.2% 4.9% -6.1%
ROE -57.99
-27.04
-76.14
-112.03
21.55
22.38
27.67
28.56
19.89
20.61
19.64
growth rate 0.0% 0.0% 0.0% 100.0% 3.9% 23.6% 3.2% -30.4% 3.6% -4.7%
ROIC -63.98
-23.09
-66.20
-113.15
17.78
20.44
26.63
27.95
19.34
19.81
17.05
growth rate 0.0% 0.0% 0.0% 100.0% 15.0% 30.3% 5.0% -30.8% 2.4% -13.9%
Cur. Ratio 2.41
1.83
1.55
1.40
1.87
4.22
8.85
11.90
18.52
16.77
14.88
growth rate -24.1% -15.3% -9.7% 33.6% 125.7% 109.7% 34.5% 55.6% -9.5% -11.3%
Quick Ratio 1.55
1.29
1.19
1.39
1.87
4.22
8.85
11.90
18.52
16.77
14.88
growth rate -16.8% -7.8% 16.8% 34.5% 125.7% 109.7% 34.5% 55.6% -9.5% -11.3%
Leverage 1.71
2.30
3.22
4.42
2.63
1.41
1.12
1.09
1.05
1.06
1.08
growth rate 34.5% 40.0% 37.3% -40.5% -46.4% -20.6% -2.7% -3.7% 1.0% 1.9%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 174.66
975.67
636.69
1,327.00
2,990.00
growth rate 458.6% -34.7% 108.4% 125.3%
Acct.Payable 31.99
22.27
growth rate -30.4%
Cur.Assets 3,667.89
4,897.64
6,059.43
7,433.00
13,961.00
growth rate 33.5% 23.7% 22.7% 87.8%
Total Assets 3,902.55
5,238.24
6,602.94
8,461.00
15,144.00
growth rate 34.2% 26.1% 28.1% 79.0%
Cash 873.99
307.02
1,347.55
533.00
3,552.00
growth rate -64.9% 338.9% -60.5% 566.4%
Cur.Liabilities 414.40
411.54
327.12
444.00
938.00
growth rate -0.7% -20.5% 35.7% 111.3%
Liabilities 415.83
411.54
330.75
447.00
1,096.00
growth rate -1.0% -19.6% 35.2% 145.2%
Equity 3,486.72
4,826.70
6,272.19
8,014.00
14,048.00
growth rate 38.4% 30.0% 27.8% 75.3%
Common Shares 449.00
449.00
449.00
460.00
519.00
573.00
608.00
618.00
621.00
620.00
636.00
growth rate 0.0% 0.0% 2.5% 12.8% 10.4% 6.1% 1.6% 0.5% -0.2% 2.6%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 9.44
12.25
88.51
72.00
79.00
growth rate 29.8% 622.3% -18.7% 9.7%
Cash From OA 311.45
327.72
1,588.97
1,015.00
1,326.00
growth rate 5.2% 384.9% -36.1% 30.6%
FCF per Share 0.10
0.02
-0.06
0.01
-0.01
0.15
0.30
0.14
0.30
growth rate -55.3% -100.0% 100.0% -100.0% 100.0% 100.0% -53.3% 114.3%
FCF -587.00
258.00
-444.00
62.00
-138.00
57.00
176.00
295.00
1,500.00
537.00
1,215.00
growth rate 100.0% -100.0% 100.0% -100.0% 100.0% 208.8% 67.6% 408.5% -64.2% 126.3%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 1,133.04
1,816.12
2,365.44
3,025.00
5,366.00
growth rate 60.3% 30.3% 27.9% 77.4%
Op.Income 554.16
1,052.83
1,366.39
1,380.00
2,638.00
growth rate 90.0% 29.8% 1.0% 91.2%
IBT 757.53
1,130.22
1,063.72
1,612.00
2,859.00
growth rate 49.2% -5.9% 51.5% 77.4%
Net Income 763.51
1,187.08
1,103.55
1,472.00
2,166.00
growth rate 55.5% -7.0% 33.4% 47.2%
EPS -2.25
-0.71
-1.33
-1.06
0.21
0.53
1.26
1.92
1.77
2.37
3.40
growth rate 0.0% 0.0% 0.0% 100.0% 152.4% 137.7% 52.4% -7.8% 33.9% 43.5%
Gross Profit 1,133.04
1,816.12
2,365.44
3,025.00
5,366.00
growth rate 60.3% 30.3% 27.9% 77.4%
R&D 487.66
660.88
852.06
1,431.00
2,386.00
growth rate 35.5% 28.9% 68.0% 66.7%

Quarterly Statements

Item Name Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Earnings BIT 350.73
2,176.02
71.00
4,497.00
858.00
growth rate 520.4% -96.7% 6,233.8% -80.9%
Balance Sheet Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Acct.Receivable 1,139.45
2,990.00
1,130.00
6,359.00
2,035.00
growth rate 162.4% -62.2% 462.7% -68.0%
Cur.Assets 12,256.30
13,961.00
14,090.00
19,141.00
19,504.00
growth rate 13.9% 0.9% 35.9% 1.9%
Total Assets 13,330.30
15,144.00
15,303.00
20,683.00
21,522.00
growth rate 13.6% 1.1% 35.2% 4.1%
Cash 4,643.04
3,552.00
5,543.00
6,605.00
8,892.00
growth rate -23.5% 56.1% 19.2% 34.6%
Cur.Liabilities 654.77
938.00
740.00
2,009.00
2,258.00
growth rate 43.3% -21.1% 171.5% 12.4%
Liabilities 815.67
1,096.00
905.00
2,812.00
3,045.00
growth rate 34.4% -17.4% 210.7% 8.3%
LT Debt
growth rate
Equity 12,514.63
14,048.00
14,398.00
17,871.00
18,477.00
growth rate 12.3% 2.5% 24.1% 3.4%
Common Shares 64.99
65.00
65.00
65.00
65.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Capital Expenditures 23.16
20.27
58.00
145.00
46.00
growth rate -12.5% 186.2% 150.0% -68.3%
Cash From OA 319.07
174.91
2,192.00
-39.00
5,078.00
growth rate -45.2% 1,153.2% -100.0% 100.0%
FCF 295.91
154.64
2,134.00
-184.00
5,032.00
growth rate -47.7% 1,280.0% -100.0% 100.0%
Income Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Sales 1,039.84
2,961.23
892.00
5,451.00
1,724.00
growth rate 184.8% -69.9% 511.1% -68.4%
Op.Income 350.73
2,176.02
71.00
4,497.00
858.00
growth rate 520.4% -96.7% 6,233.8% -80.9%
IBT 699.28
1,955.17
354.00
4,328.00
671.00
growth rate 179.6% -81.9% 1,122.6% -84.5%
Net Income 537.05
1,471.86
269.00
3,378.00
530.00
growth rate 174.1% -81.7% 1,155.8% -84.3%
Gross Profit 1,039.84
2,961.23
892.00
5,451.00
1,724.00
growth rate 184.8% -69.9% 511.1% -68.4%
R&D 607.89
668.66
715.00
775.00
721.00
growth rate 10.0% 6.9% 8.4% -7.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (81.57)

YOY Growth Grade:

C (66.44)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is undefined, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE 16.89
EPS / Growth

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 40.0% 50.0% 52.4%
Future PE 0.01 11.26 40.53
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT

Graham Number:

Current EPS is undefined, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.